Similar articles

• [Treatment of chronic hepatitis C in special groups].

  Bourlière M, Halfon P, Portal I. Bourlière M, et al. Gastroenterol Clin Biol. 2002 Apr;26 Spec No 2:B238-47. Gastroenterol Clin Biol. 2002. PMID: 12180296 Review. French. No abstract available.
• [Treatment of patients with chronic hepatitis C who have not been previously treated].

  Marcellin P, Boyer N. Marcellin P, et al. Gastroenterol Clin Biol. 2002 Apr;26 Spec No 2:B194-201. Gastroenterol Clin Biol. 2002. PMID: 12180288 Review. French. No abstract available.
• Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection.

  Sulkowski MS, Wasserman R, Brooks L, Ball L, Gish R. Sulkowski MS, et al. J Viral Hepat. 2004 May;11(3):243-50. doi: 10.1111/j.1365-2893.2004.00490.x. J Viral Hepat. 2004. PMID: 15117326 Clinical Trial.
• [Chronic hepatitis C: apart from antiviral treatment what other measures should be recommended?].

  Larrey D. Larrey D. Gastroenterol Clin Biol. 2002 Apr;26 Spec No 2:B283-90. Gastroenterol Clin Biol. 2002. PMID: 12180302 Review. French. No abstract available.
• [Probable cutaneous sarcoidosis associated with combined ribavirin and interferon-alpha therapy for chronic hepatitis C].

  Savoye G, Goria O, Herve S, Riachi G, Noblesse I, Bastien L, Courville P, Lerebours E. Savoye G, et al. Gastroenterol Clin Biol. 2000 Jun-Jul;24(6-7):679. Gastroenterol Clin Biol. 2000. PMID: 10962394 French. No abstract available.